ALDX: Reproxalap's Third FDA Decision is the Ultimate Binary Event
Aldeyra Therapeutics faces its third FDA decision on reproxalap for dry eye disease on March 16. Two prior rejections, $15M in debt due two weeks later, and an AbbVie deal hanging in the balance. This is make or break.
